AACR 2026: QLS5132, a CLDN6-Targeted ADC, Demonstrates Clinical Benefit in Advanced Platinum-Resistant Ovarian Cancer
Patients treated with QLS5132, a novel antibody-drug conjugate (ADC) developed by Qilu Pharmaceutical Co. experienced clinical benefit. This conclusion is based on results from a phase 1 clinical study presented at the annual meeting of the American Association for Cancer Research, held April 17 - 22. 2026, in San Diego Ca.
Phase 1/2 Data for JK06, a 5T4-Targeted Antibody-Drug Conjugate, Shows Promising Results
Data from a Phase 1/2 dose-escalation and expansion study of JK06, a 5T4-targeted antibody-drug conjugate (ADC) being developed by SalubrisBio, have shown promising results...
Breakthroughs in Urothelial Carcinoma: New Insights from 2026 EAU Congress on Disitamab Vedotin
Breakthroughs in Urothelial Carcinoma: New Insights from 2026 EAU Congress on Disitamab Vedotin
First-in-Patient Phase I Combination Study of IDE849 and IDE161 in DLL3 Upregulated Solid Tumor...
The first patient (FIP) has been dosed in a Phase 1 clinical trial combining IDE849 (also known as SHR-4849), a potential first-in-class delta-like ligand 3 (DLL3)-targeting Topoisomerase I (Topo-I-) payload antibody drug conjugate (ADC), with IDE161, a potential first-in-class poly(ADP-ribose) glycohydrolase (PARG) inhibitor. Both drugs are being developed by IDEAYA Biosciences. The Phase 1 combination study will be evaluated in DLL3 upregulated solid tumor indications, including small cell lung cancer (SCLC), neuroendocrine tumors (NETs), neuroendocrine carcinomas (NECs), and melanoma.
AbbVie and RemeGen to Jointly Develop a Novel Bispecific Antibody for Advanced Solid Tumors
AbbVie and RemeGen to Jointly Develop a Novel Bispecific Antibody for Advanced Solid Tumors
Sichuan Kelun-Biotech Signs Collaborative Agreement with Crescent Biopharma; Receives IND and BTD from Chinese...
The Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China has approved an Investigational New Drug (IND) application for SKB105 (also known as CR-003 and PR-023), integrin beta-6 (ITGB6)-targeted antibody-drug conjugate (ADC) being developed by Sichuan Kelun-Biotech Biopharmaceutical, for the treatment of advanced solid tumors.
TUB-040: A Next-Generation NaPi2b-Targeted ADC for Ovarian and Lung Cancer
TUB-040: A Next-Generation NaPi2b-Targeted ADC for Ovarian and Lung Cancer
Izalontamab Brengitecan Receives U.S. FDA Breakthrough Therapy Designation Advanced EGFR-Mutated Non-Small Cell Lung Cancer
Izalontamab Brengitecan Receives U.S. FDA Breakthrough Therapy Designation Advanced EGFR-Mutated Non-Small Cell Lung Cancer
Zocilurtatug Pelitecan Shows Clinical Benefit as a Potential First-in-Class DLL3-Targeted ADC Against Previously Treated...
Updated data from the global Phase 1 clinical trial of zocilurtatug pelitecan (zoci; formerly known as ZL-1310; see ADC Drugmap; NCT06179069)* an antibody-drug conjugate...
AACR-NCI-EORTC: Preliminary Efficacy Data + Tolerable Safety Profile, Reinforce the potential of ZW191...
Preliminary results from the ongoing Phase 1 study (NCT06555744) evaluating ZW191, an antibody-drug conjugate (see ADC Drugmap) targeting folate receptor-alpha (FR⍺), were presented at...
